PetVivo Holdings Inc · OTC:PETV
PetVivo — Investor Presentation (December 2024)
24 slides from PetVivo's investor presentation, Dec 26, 2024
Slide 1: Investor Presentation December 2024
Investor Presentation December 2024 PETV (OTCQB) PetVivo Holdings, Inc.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those
Slide 3: Company Highlights
Company Highlights . Focus on estimated $11B companion animal veterinary care and product sales market Spryng™, with our OsteoCushion™ Technology, is a veterinary device that promotes the restoration of joint mechanics for the management of lameness and other joint-related afflictions including oste
Slide 4: Osteoarthritis (OA) Opportunity
Osteoarthritis (OA) Opportunity $11B Veterinary Care and Product Sales Market Osteoarthritis: Current solutions treat symptoms, but do a common affliction of the joints not manage the cause * Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are approved to alleviate pain and inflammation: - Known to ca
Slide 5: The Optimal OA Solution: Spryng with OsteoCushion Technology
The Optimal OA Solution: Spryng with OsteoCushion Technology ° Spryng provides a biocompatible lubricious and viscoelastic biomaterial, which promotes the restoration of joint mechanics to improve joint function - Similar components/function found in natural cartilage (i.e. collagen, elastin and hep
Slide 6: Spryng with OsteoCushion Technology
Spryng with OsteoCushion Technology ° Spryng is a unique new medical device addressing the root cause of the affliction, not just the symptoms ° Purified natural components self-assemble to form an insoluble, hydrated matrix - Protein source bovine tissues (i.e. collagen and elastin) from isolated h
Slide 7: Spryng Mechanism of Action
Spryng Mechanism of Action * An animal suffering from osteoarthritis generally exhibits damaged and/or lost cartilage thereby creating bone on bone contact that results in an increase of joint inflammation, pain and further loss of cartilage ° Spryng reinforces synovial membrane function, without ph
Slide 8: Spryng Canine Success: Buggy
CONDITION 13-year-old mixed breed. Last 2 years mobility issues have worsened. Led a very active lifestyle until the last 6 years exhibited painful mobility: often trembled with movement. Unable to run and play outside with the other dogs as she loves to do. Orthopedic exam revealed decreased range-
Slide 9: Spryng Equine Case Study: Fergie
Spryng Equine Case Study: Fergie See other equine case studies online. See Tinker Case Study here. 1) Results to vary per animal HISTORY 16-year-old Saddlebred mare. Fergie shows as a Saddlebred monthly and ridden 5-6 days per week. However, due to apparent discomfort, she had become choppy, awkward
Slide 10: Spryng Competitive Distinctions
Spryng Competitive Distinctions Outcomes address affliction/not just symptoms 7 Current treatments rely on biologic = 7 activity to treat symptoms; Spryng Spryng CANIN provides structural components to address affliction 7 Price/Cost advantage é Derived from all natural materials - Ease of applicati
Slide 11: Spryng: Product Category Comparison
Spryng: Product Category Comparison FEATURES Injections per Year Benefits Last up to 12 Months or More Bioscaffold From No Synthetic or Radioactive Material Research Supports Joint Health Benefits No Drug Interactions & All Stages of Osteoarthritis Composition/Source Material Naturally-Derived Compo
Slide 12: Distribution Services Agreements: Cencora (MWI) and Covetrus
Distribution Services Agreements: Cencora (MWI) and Covetrus MWI - PetVivo Distribution Services Agreement Terms: Non-exclusive distribution agreement with ongoing annual renewal option until terminated by either party Designated distributor for PetVivo’s veterinary medical device, Spryng with Osteo
Slide 13: Spryng Tolerance Studies
Spryng Tolerance Studies % spryng with OsteoCushion” Technology rt Canine Tolerance Purpose: Assess tolerance of Spryng™ administration in dogs. Design: 20 healthy dogs received intra-articular injection with saline or Spryng in contralateral shoulder, hip, elbow, and stifle joints in a randomized s
Slide 14: Spryng Clinical Studies
Spryng Clinical Studies % spryng with OsteoCushion” Technology Canine Hip OA CASE ETH os SCOLORADO ANIMAL SPECIALTY BEMERGENCY VETERINARY HEALTH Purpose: Study the effects of Collagen-Elastin Hydrogel Microparticles (Spryng) on pain & function secondary to hip osteoarthritis in dogs. Investigators:
Slide 15: New Spryng Clinical Trials
New Spryng Clinical Trials & spryng Underway or Recently Completed, Awaiting Publication oe Canine Study at Colorado State University Canine Study Principal investigators: Felix Duerr, DVM, Principal investigators: MS, Dr. med. vet., CCRT, DACVS-SA, DECVS, Jamie Gaynor DVM, MS, DACVA, DAAPM DACVSSMR
Slide 16: State-of-the-Art Production Facilities
State-of-the-Art Production Facilities ¢ Spryng product is manufactured in PetVivo’s ISO certified cleanrooms (ISO 8 to ISO 7 to ISO 5 ° Initial batch sizes of approx. 2,000 syringes; planning to increase to batches of 5,000+ syringes per month. ° Current production facility annual capacity is appro
Slide 17: Comprehensive IP Portfolio
Comprehensive IP Portfolio ¢ 12 US Patents and 9 Foreign Patents ¢ Broad Claim Language - “Comprising” Transitions ° Our Patents & Trade Secrets Protect: ¢ Protein & Carbohydrate Based Thermoplastics ¢ Biomaterials of Many Compositions ¢ Medical, Drug Delivery & Combination Products ¢ Medical & Phar
Slide 18: Pet Product Pipeline (FDA clearance not required)
Pet Product Pipeline (FDA clearance not required) Product .. .. 7 Commercial Raticie Basedbevices | species | sary | mot | atsey | Sozcae VD-01 Osteoarthritis Canine (Spryng™) VD-02 Osteoarthritis Equine (Spryng™) 932021 | VD-03 Digital Cushion Lameness Equine (Brand TDB) »> VD-04 Urinary Incontinen
Slide 19: Market Overview: Companion Animal/Veterinarian
Market Overview: Companion Animal/Veterinarian * US Pet Spend increased from $123.6B in 2021 to $138.0B in 2022 ¢ Veterinary care and products is a leading growth driver - $11B in 2021 in US 66% of US Households own a pet - 83.0M Dogs; 50.0M Cats * Approximately 7.2M horses in US* * Pet owners’ spen
Slide 20: Management Team Introduction
Management Team Introduction Deep Bench of Industry Veterans with Decades of Experience e @ John Lai Garry Lowenthal Randall Meyer John F. Dolan April Boyce Bryan S. Monninger CEO, President & Director CFO coo General Counsel VP of Marketing VP of Sales Dewees a A TRAUST PG & Novus €p ROX Deloitte.
Slide 21: Strong Board of Directors and Advisors
Strong Board of Directors and Advisors &0o8 80Be 8 @ Michael Eldred Joseph Jasper Robert Rudelius Diane Levitan Robert Costantino Spencer Breithaupt _ John Lai Director Director Director Director Director Director Director & CEO 2) BuueEarth WES FINANCIAL I MWr Animal Health [ge] Vermillion () Ps .
Slide 22: Growth Drivers
Growth Drivers ° Expand Sales Force and Distribution ¢ Add regional sales managers ¢ Distributor networks « Vetcove @idec. 2021) * MWIDSA (June 2022) * Covetrus DSA (December 2023) ¢ Increase KOL Adoption ¢ Used by veterinarians in more than 600 clinics in 49 states * Podium presentations at confere
Slide 23: PetVivo Highlights
PetVivo Highlights a Large market opportunity - $11B Veterinary Care and Products Market and growing 8 Increased humanization of companion animals driven by Covid-19 pandemic Spryng is an optimal solution for the management of OA over the current treatments treatments: NSAIDs, Corticosteroids, HA, s
Slide 24: John Lai
John Lai Chief Executive Officer jlai@petvivo.com (952) 405-6216 PetVivo.com To order, contact infol@petvivo.com or 844-PET-VIVO (844-738-8486) Spryng™ with OsteoCushion™ Technology is a veterinary medical device by PetVivo, Inc. Spryng™ is a trademark of PetVivo Holdings, Inc. This product is cover
PetVivo Holdings — Investor Presentation (December 2024) on 6ix